Lacripep is under clinical development by TearSolutions and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lacripep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lacripep overview
Lacripep is under development for the treatment of primary Sjogren’s syndrome dry eye. It is administered by ophthalmic route and formulated in the form of solution (drops). The drug candidate is a synthetic fragment of lacritin.
TearSolutions overview
TearSolutions is a biopharmaceutical company. It focuses on discovery and development of topical drugs to treat dry eye syndrome. TearSolutions is investigating Lacripep, a topical synthetic tear protein fragment of lacritin that restores tearing and treat dry eye associated with primary sjogren’s syndrome. The company is a spin-out from the University of Virginia. TearSolutions is headquartered in Charlottesville, Virginia, the US .
For a complete picture of Lacripep’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
